KalVista Pharmaceuticals, Inc. (KALV) financial statements (2021 and earlier)

Company profile

Business Address 55 CAMBRIDGE PARKWAY
CAMBRIDGE, MA 02142
State of Incorp. DE
Fiscal Year End April 30
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

1/31/2020
TTM
4/30/2019
4/30/2018
4/30/2017
12/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments81101513154
Cash and cash equivalents1932513154
Short-term investments6269   
Receivables  73 
Other undisclosed current assets1815111
Total current assets:99116593455
Noncurrent Assets
Operating lease, right-of-use asset1
Property, plant and equipment22201
Restricted cash and investments    0
Other noncurrent assets000 1
Total noncurrent assets:43202
TOTAL ASSETS:103118613457
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities88533
Accounts payable33111
Accrued liabilities56321
Deferred revenue1
Debt100 1
Deferred revenue and credits  0
Contract with customer, liability10
Other undisclosed current liabilities  18  
Total current liabilities:10182334
Noncurrent Liabilities
Long-term debt and lease obligation1 0 3
Long-term debt, excluding current maturities    3
Capital lease obligations 0  
Operating lease, liability1
Liabilities, other than long-term debt33  0
Deferred revenue and credits  0
Deferred revenue3
Contract with customer, liability3
Other undisclosed noncurrent liabilities  11  
Total noncurrent liabilities:3311 3
Total liabilities:13213437
Stockholders' equity
Stockholders' equity attributable to parent9097273149
Common stock00000
Additional paid in capital20619110090122
Accumulated other comprehensive loss(1)(2)(1)(3) 
Accumulated deficit(115)(92)(72)(56)(73)
Total stockholders' equity:9097273149
TOTAL LIABILITIES AND EQUITY:103118613457

Income statement (P&L) ($ in millions)

1/31/2020
TTM
4/30/2019
4/30/2018
4/30/2017
12/31/2015
Revenue, net 20
Gross profit:1216820
Operating expenses(55)(46)(27)(24)(21)
Operating loss:(43)(30)(19)(22)(21)
Nonoperating income (expense)12934(4)
Investment income, nonoperating21000
Foreign currency transaction gain (loss), before tax00(2)1 
Other nonoperating income108421
Interest and debt expense    (3)
Loss from continuing operations before income taxes:(31)(21)(16)(19)(28)
Income tax expense (0)   
Other undisclosed loss from continuing operations(0)    
Net loss:(31)(21)(16)(19)(28)
Other undisclosed net income attributable to parent    3
Net loss available to common stockholders, diluted:(31)(21)(16)(19)(25)

Comprehensive Income ($ in millions)

1/31/2020
TTM
4/30/2019
4/30/2018
4/30/2017
12/31/2015
Net loss:(31)(21)(16)(19)(28)
Other comprehensive income1    
Other undisclosed comprehensive income1    
Comprehensive loss:(30)(21)(16)(19)(28)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(1)(1)2(3) 
Comprehensive loss, net of tax, attributable to parent:(30)(22)(14)(21)(28)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: